GSK 2330811

Drug Profile

GSK 2330811

Alternative Names: GSK2330811

Latest Information Update: 17 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories; Antifibrotics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Oncostatin M inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic scleroderma

Most Recent Events

  • 05 Jun 2017 Phase-II clinical trials in Systemic scleroderma in United Kingdom (SC) (NCT03041025)
  • 11 Nov 2016 Safety and pharmacokinetics data from a phase I trial in Systemic scleroderma (In healthy volunteers) presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 27 Jul 2016 GlaxoSmithKline plans a phase II trial in Systemic scleroderma (NCT03041025)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top